Background: Current guidelines recommend non–vitamin K antagonist oral anticoagulants
(NOACs) as the first-choice therapy in patients with nonvalvular atrial fibrillation because …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and
oral anticoagulation therefore is the essential part of AF management to reduce the risk of …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Several observational studies have compared the effectiveness and safety outcomes
between nonvitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists …

ContextPatients with nonvalvular atrial fibrillation (AF) have an increased risk of stroke and
other vascular events. ObjectiveTo compare the risk of vascular and bleeding events in …

Background The aim of the present meta-analysis was to evaluate the effectiveness and
safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

Atrial fibrillation (AF) is a major cause of ischaemic stroke. The majority of these strokes can
be prevented by treatment with oral anticoagulation therapy. The advent of non-vitamin K …